JumpStarting Drug Review
The JumpStart service is modernizing the drug review process—medical reviewers are using this service to quickly and thoroughly assess data from drug clinical trials, ensuring safe and effective products are approved for public use.
In July 2014, JumpStart was recognized as a "Secretary's Pick" by Secretary Sylvia Matthews Burwell and Deputy Secretary Bill Corr at the HHS Inovates Ceremony. The projects are listed in the HHS Idea Lab.
What is JumpStart?
JumpStart runs a series of drug clinical trial data analyses early in the review process to assess data composition, quality, analyses options, and tools for the analyses, so reviewers better understand the data and have the information to conduct an effective evaluation of the drug submission.
JumpStart provides these data findings to the reviewers within two weeks of the receipt of a new submission, giving reviewers time to clarify issues or make requests of the organizations developing the drug before proceeding in the review process. JumpStart also provides data analyses that highlight areas of concern and may warrant further attention.
JumpStart Benefits and Impact
JumpStart is transforming the scientific regulatory review process in several ways:
The JumpStart data fitness assessment and exploratory safety analyses are improving the review process for getting safe and effective drug products to the market.
The initial assessment on data fitness gives reviewers and sponsors the opportunity to address potential issues early on in the review cycle and avoid delays.
By providing targeted exploratory safety analysis, JumpStart enhances the efficiency of safety signal identification and risk analysis. This has a direct impact on patients who expect the approval of safe and effective products that are appropriately labeled for marketing.
JumpStart work session discussions encourage collaboration and communication among different disciplines and informatics experts. By building and enhancing these ties with one another, reviewers and informatics experts can improve and speed communication with sponsors to resolve data issues or questions.
JumpStart provides an opportunity for clinical reviewers to take advantage of modern tools and technologies, and expose more people to technical innovation.
For more information contact Office of Computational Science.
More Information on JumpStarting Drug Review
- Return to OCS Home Page
- Office of Computational Science Supports the Regulatory Review Process
- Scientific Collaborations